Inquis Medical, Inc.

Inquis Medical, Inc. is a clinical-stage medical device company based in Menlo Park, California. Founded in 2019 or 2020 by Vahid Saadat and Mojgan Saadat, the company specializes in innovations for treating venous thromboembolic (VTE) diseases, such as pulmonary embolism (PE) and deep vein thrombosis (DVT). With a mission of "care without compromise," Inquis Medical focuses on developing efficient and precise treatments that minimize blood loss during interventions.

The company's flagship product is the AVENTUS Precision Thrombectomy System, a catheter-based device designed for clot removal in VTE treatments. It features advanced technologies like TrueClot™ Sensing for real-time tissue differentiation, directional aspiration for precise targeting, and integrated blood return to enhance procedural efficiency. The AVENTUS system received FDA 510(k) clearance for PE treatment in June 2025, following successful clinical trial results. Inquis Medical has raised $40 million in funding to support the development of its thrombectomy technologies and employs around 27 people.